Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | 212Pb-ADVC001 |
| Synonyms | |
| Therapy Description |
212Pb-ADVC001 is a radioligand therapy comprising ADVC001, a PSMA-targeting small molecule ligand, linked to the radionuclide 212Pb, which potentially induces antitumor activity (J Nucl Med 65 (supplement 2) (Jun 2024): 242474). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| 212Pb-ADVC001 | 212Pb-ADVC001 is a radioligand therapy comprising ADVC001, a PSMA-targeting small molecule ligand, linked to the radionuclide 212Pb, which potentially induces antitumor activity (J Nucl Med 65 (supplement 2) (Jun 2024): 242474). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05720130 | Phase Ib/II | 212Pb-ADVC001 | Phase Ib/IIa Dose Escalation and Expansion Study of [²¹²Pb]Pb-ADVC001 in Metastatic Castration Resistant Prostate Cancer (TheraPb - Phase I/II Study). | Recruiting | AUS | 0 |